Share on StockTwits
 

FBR Capital Markets decreased their price target on shares of Quest Diagnostics (NYSE:DGX) from $68.00 to $60.00 in a research note issued on Monday, American Banking and Market News reports. The firm currently has a “market perform” rating on the stock. FBR Capital Markets’ target price would suggest a potential upside of 11.71% from the company’s current price.

Quest Diagnostics (NYSE:DGX) traded up 0.41% during mid-day trading on Monday, hitting $53.93. The stock had a trading volume of 534,272 shares. Quest Diagnostics has a 1-year low of $51.90 and a 1-year high of $64.10. The stock’s 50-day moving average is $54.39 and its 200-day moving average is $58.88. The company has a market cap of $7.843 billion and a price-to-earnings ratio of 11.02.

Several other analysts have also recently commented on the stock. Analysts at JMP Securities initiated coverage on shares of Quest Diagnostics in a research note to investors on Wednesday, December 18th. They set a “market perform” rating on the stock. Separately, analysts at Morgan Stanley reiterated an “underweight” rating on shares of Quest Diagnostics in a research note to investors on Thursday, December 12th. They now have a $58.00 price target on the stock. Finally, analysts at Citigroup Inc. reiterated a “neutral” rating on shares of Quest Diagnostics in a research note to investors on Wednesday, December 11th. They now have a $58.00 price target on the stock, down previously from $59.00. Five investment analysts have rated the stock with a sell rating, fifteen have issued a hold rating and four have assigned a buy rating to the stock. Quest Diagnostics presently has an average rating of “Hold” and a consensus target price of $59.37.

Quest Diagnostics Incorporated (NYSE:DGX)is a provider of diagnostic testing, information and services, providing insights that enable patients and physicians to make healthcare decisions.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.